Hits:

Indexed by:期刊论文

Date of Publication:2017-11-01

Journal:MEDICINA INTENSIVA

Included Journals:SCIE、PubMed

Volume:41

Issue:8

Page Number:475-482

ISSN No.:0210-5691

Key Words:Acute coronary syndrome; Thrombin activatable fibrinolysis inhibitor; Proinflammatory cytokine; Acute phase protein; Coronary disease

Abstract:Objective: A study was made of the changes in the serum levels of thrombin activatable fibrinolysis inhibitor (TAFI), proinflammatory cytokines and acute phase proteins in the acute stage of acute coronary syndrome (ACS), in order to explore the possibility of using TAFI as a biomarker for ACS risk assessment.
   Methods: A total of 211 patients with ACS were enrolled, and healthy subjects were used as controls. Blood samples were taken within 24 h after admission. Serum TAFI levels were determined by immunoturbidimetry. Serum levels of interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were determined by enzyme linked immunosorbent assay (ELISA). Procalcitonin (PCT) and C-reactive protein (CRP) levels were measured by gold-immunochromatographic assay.
   Results: Serum TAFI levels in ACS patients were significantly decreased versus the controls. The IL-1 beta, IL-6, TNF-alpha, PCT and CRP levels were markedly higher in the ACS patients than in the controls. Correlation analysis revealed a strong negative correlation between TAFI concentration and the IL-1 beta, IL-6, TNF-alpha, PCT and CRP levels in ACS patients and in controls. Multivariate logistic regression analysis suggested decreased serum TAFI to be an independent risk factor for ACS (OR 9.459; 95% CI 2.306-38.793; P = 0.002). The area under the receiver operating characteristic (ROC) curve for TAFI was 0.872 (95% CI 0.787-0.909; P < 0.001). The optimum TAFI cutoff point for the prediction of ACS was 24 mu g/ml, with a sensitivity of 75.83% and a specificity of 72.57%.
   Conclusion: These findings suggest that TAFI can be useful as a potential biomarker for ACS risk assessment. (C) 2016 Elsevier Espana, S.L.U. y SEMICYUC. All rights reserved.